What is the recommended management for a symptomatic submucosal uterine fibroid in a reproductive‑age woman desiring fertility preservation?

Management of Symptomatic Submucosal Uterine Fibroid in Reproductive-Age Women Desiring Fertility

Hysteroscopic myomectomy is the definitive treatment of choice for symptomatic submucosal fibroids in women desiring fertility preservation. 1

Primary Recommendation: Hysteroscopic Myomectomy

For submucosal fibroids, hysteroscopic myomectomy is indicated as the procedure of choice, particularly for fibroids <5 cm. 1 This approach directly addresses the fertility concerns while providing symptom relief:

Why Hysteroscopic Myomectomy is Optimal:

• Fertility preservation: Submucosal fibroids significantly reduce pregnancy chances and increase complications 2. Surgical removal via hysteroscopy is the gold standard for FIGO Type 0,1, and 2 submucosal fibroids in women desiring pregnancy 2

• Symptom resolution: Provides equivalent improvement in symptom scores and quality of life compared to more invasive surgical approaches at 2-3 months 1

• Faster recovery: Associated with shorter hospitalization and faster return to usual activities compared to laparoscopic or open myomectomy 1

• Cavity restoration: Hysteroscopic myomectomy is the preferred treatment to restore normal uterine cavity structure, which is critical for fertility 3

Important Caveats About Fertility Evidence:

The evidence on fertility improvement after hysteroscopic myomectomy has limitations. Two randomized controlled trials showed conflicting results—one showed no difference in pregnancy rates, while another showed improvement but with data inconsistencies 1. Neither study reported live birth rates, and miscarriage rates were 30-50% in one study 1. However, retrospective data demonstrates pregnancy rates of 85% with live birth rates of 65% after hysteroscopic myomectomy 1.

Surgical Risks to Discuss:

• Uterine perforation
• Fluid overload
• Need for blood transfusion
• Bowel or bladder injury
• Endomyometritis
• Need for reintervention 1

Medical Management: Temporizing Measures Only

Medical management can be considered only as a bridge to surgery or for symptom control, not as definitive treatment in fertility-desiring patients:

First-Line Medical Options:

• NSAIDs
• Estrogen-progestin oral contraceptive pills
• Tranexamic acid (nonhormonal alternative) 1

Second-Line (Preoperative Fibroid Reduction):

• GnRH agonists (leuprolide acetate) or GnRH antagonists (elagolix, linzagolix, relugolix) can reduce tumor volume and are commonly used short-term to decrease fibroid size before surgery 1
• Critical limitation: Fertility is suppressed during treatment, and symptoms rapidly recur after cessation 1
• Hypoestrogenic effects include headaches, hot flushes, hypertension, and bone mineral density loss 1

What NOT to Do:

Avoid these interventions in fertility-desiring patients:

• Endometrial ablation: Associated with high risk of pregnancy complications 1
• Hysterectomy: Causes permanent, irreversible infertility 1
• Uterine artery embolization (UAE): Not recommended for women desiring pregnancy. While myomectomy showed improved quality of life at 2 years compared to UAE, reproductive outcomes following myomectomy are superior with higher clinical pregnancy and live birth rates 1, 4

Clinical Algorithm:

1. Confirm diagnosis: Pelvic ultrasound or MRI to characterize fibroid location, size, and number 1

2. Assess fibroid characteristics:

   • Submucosal fibroids <5 cm are ideal for hysteroscopic approach 1
   • Larger fibroids may require two-stage procedures or pretreatment with GnRH agonists/antagonists 5

3. Evaluate for concurrent pathology: Consider endometrial biopsy if presentation raises concern for other causes of heavy menstrual bleeding 1

4. Proceed with hysteroscopic myomectomy as definitive treatment

5. Consider preoperative GnRH therapy only if fibroid size necessitates reduction before surgery 1

Key Pitfall to Avoid:

Do not rely on medical management alone in fertility-desiring patients. While GnRH agonists/antagonists reduce bleeding and fibroid volume, they suppress fertility during treatment and symptoms recur rapidly after cessation 1. These should only be used as preoperative adjuncts, not as primary therapy.

Patients with significant intramural or subserosal fibroid burden with concomitant adenomyosis are less likely to experience symptom relief from hysteroscopic myomectomy alone 1—these patients may require additional surgical approaches.